Incyte Corporation reported strong financial results for the third quarter of 2026, with total revenue reaching $1.56 billion, significantly exceeding consensus estimates. The performance was anchored by a major beat in Jakafi net sales and robust growth in the core business, particularly Opzelura. While the company reported a GAAP net loss of $784.8 million, this was primarily due to a one-time $1.23 billion R&D charge associated with the Vega Therapeutics acquisition. Management raised full-year 2026 guidance for total net sales and specific product lines to reflect this continued commercial momentum.
Key Highlights
- Total net sales grew 14% year-over-year to $1.32 billion, driven by double-digit demand growth across marketed products.
- Jakafi net sales reached $827 million, a 4% increase year-over-year, significantly outperforming the $738 million estimate due to a 12% rise in paid demand.
- Opzelura net sales surged 36% to $255 million, supported by increased demand in atopic dermatitis and vitiligo indications.
- The acquisition of Vega Therapeutics added latarcibart, a Phase 3 candidate for von Willebrand disease, to the late-stage pipeline.